We serve Chemical Name:methyl 3-benzamidopropanoate CAS:89928-06-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:methyl 3-benzamidopropanoate
CAS.NO:89928-06-3
Synonyms:3-benzoylaminopropionic acid methyl ester
Molecular Formula:C11H13NO3
Molecular Weight:207.22600
HS Code:2924299090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:401.7ºC at 760 mmHg
Density:1.133g/cm3
Index of Refraction:1.519
PSA:55.40000
Exact Mass:207.09000
LogP:1.37040
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-benzoylaminopropionic acid methyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-benzoylaminopropionic acid methyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-benzoylaminopropionic acid methyl ester Use and application,3-benzoylaminopropionic acid methyl ester technical grade,usp/ep/jp grade.
Related News: The growing use of biocatalysis in pharmaceutical chemistry promises to deliver on this need, while also offering substantial cost savings and faster time to market for urgently needed therapeutics. 3-bromo-N-phenylbenzenecarboximidoyl cyanide manufacturers “The jury was careful and awarded us what we’d asked for down to the penny,” Plexxikon’s lawyer Daralyn Durie told Bloomberg after the verdict came down. 2,4-Diethyl-3,5-bis-(p-fluorphenylimino)-1,2,4-thiadiazolidin suppliers “The jury was careful and awarded us what we’d asked for down to the penny,” Plexxikon’s lawyer Daralyn Durie told Bloomberg after the verdict came down. tert-butyl (S)-3-((S)-1-ethoxycarbonyl-Ω-phtalimidononyl)amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine-5-acetate vendor & factory The growing use of biocatalysis in pharmaceutical chemistry promises to deliver on this need, while also offering substantial cost savings and faster time to market for urgently needed therapeutics. ,Given ICER’s uncertainty regarding efgartigimod’s dosing and long-term benefits, the group said it’s moderately certain the drug can produce a “comparable, small or substantial net health benefit” in that same group of MG patients.
